This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Frontiers in Cardiovascular Medicine
JANUARY 28, 2025
Care for survivors after an acute attack of COVID-19 should include paying close attention to cardiovascular health and disease.Systematic Review RegistrationPROSPERO [CRD42022353965].
95 
Heart BMJ
FEBRUARY 26, 2025
One in five women suffer from hypertension worldwide, and almost half of the mortality in women is caused by cardiovascular disease (CVD) (WHO). One such transitional point is pregnancy, and the report highlights the increased risk of CVD in women who suffer from hypertension in pregnancy (HIP).
59 
Med Page Today
JUNE 6, 2024
(MedPage Today) -- Vigorous exercise appeared to preserve cognitive function in older adults with hypertension, a post hoc analysis of SPRINT MIND trial data showed. At least one vigorous physical activity session per week reduced the risk of.
128 
Med Page Today
MAY 16, 2024
(MedPage Today) -- LONG BEACH, Calif. -- Chlorthalidone was no better than hydrochlorothiazide for reducing the incidence of major renal outcomes in patients with hypertension, a secondary analysis of the randomized Diuretic Comparison Project.
119 
JAMA Cardiology
JUNE 11, 2024
This cohort study examines risk factors and characterizes outcomes for postpartum individuals with ongoing hypertension and severe hypertension following hospital discharge through a hospital system’s remote blood pressure management program.
108 
CardiacWire
FEBRUARY 11, 2024
The associations between obesity and hypertension are widely known, but a new JACC study reveals that weight-reducing gastric bypass surgery has a significant and lasting impact on patients’ need for antihypertensives. vs. 2.4%) All gastric bypass patients eliminated their resistant hypertension (from 15.2%
111 Medical Xpress - Cardiology
OCTOBER 28, 2024
University of Alabama at Birmingham researchers have discovered that a genetic risk score can predict how Black individuals with hypertension respond to the blood pressure medication chlorthalidone and their likelihood of developing treatment-resistant hypertension.
85 
Frontiers in Cardiovascular Medicine
NOVEMBER 11, 2024
AimTo evaluate the real-life effectiveness and safety of hydrogen inhalation (HI) therapy as an additional treatment in Chinese adults with hypertension.MethodsThis observational, retrospective clinical study included hypertensive patients receiving routine antihypertensives with or without HI initiation from 2018 to 2023.
59 
American College of Cardiology
MARCH 31, 2025
25 in Chicago and simultaneously published in NEJM.
61 
Open Heart
FEBRUARY 4, 2025
Background Left ventricular diastolic function as assessed by tissue Doppler echocardiography predicts cardiovascular event rates at 4 years of follow-up in patients with hypertension. Results Among 506 hypertensive patients (median age 64, interquartile range (58, 69), 87% male), there were 200 (40%) deaths over a 20-year follow-up period.
52 
Frontiers in Cardiovascular Medicine
JULY 24, 2024
Chronic Thromboembolic Pulmonary Hypertension (CTEPH) is a severe and complex condition that evolves from unresolved pulmonary embolism, leading to fibrotic obstruction of pulmonary arteries, pulmonary hypertension, and potential right heart failure.
98 
DAIC
MAY 8, 2024
Bioelectronic medicine scientists at The Feinstein Institutes for Medical Research used noninvasive, splenic focused ultrasound stimulation (sFUS) and found they can reduce inflammation and improve symptoms of pulmonary arterial hypertension (PAH). The earlier and longer the treatment was delivered, the better the outcomes.
115 
NEJM Journal Watch - Cardiology
JANUARY 8, 2025
In a secondary analysis from a randomized trial, no important differences were noted.
81 
Frontiers in Cardiovascular Medicine
MARCH 30, 2025
Demographic, clinical, and diagnostic data, as well as follow-up outcomes, were reviewed. The independent risk factors for mortality included left ventricular ejection fraction (LVEF), pulmonary hypertension, and low-density lipoprotein (LDL) levels (P<0.05).
52 
Dr. Paddy Barrett
NOVEMBER 29, 2024
Outcome over process, in my view, works best here. 1 The global epidemiology of hypertension. Hypertension. Hypertension. 6 Mortality and Morbidity Among Individuals With Hypertension Receiving a Diuretic, ACE Inhibitor, or Calcium Channel Blocker: A Secondary Analysis of a Randomized Clinical Trial. Hypertension.
Hypertension Journal
JANUARY 11, 2024
Hypertension, Ahead of Print. Although orthostatic hypotension (OH) has long been recognized as a manifestation of autonomic dysfunction, a growing body of literature has identified OH as a common comorbidity of hypertension. These strategies include countermaneuvers and short-acting vasoactive agents (midodrine, droxidopa).
81 
HCPLive
OCTOBER 4, 2024
An EADV 2024 study suggests dupilumab use during pregnancy is generally safe and may lower risks of preterm labor, gestational hypertension, and diabetes.
110 
Frontiers in Cardiovascular Medicine
FEBRUARY 24, 2025
Hypertension and diabetes were the two most common risk factors identified. Despite the fact that percutaneous coronary intervention is the standard of care in one subset of acute coronary syndrome, significant number of patients were treated medically due to the limited service in the setting. were male, with the average age of 56.313.5
98 
DAIC
JANUARY 19, 2024
The BACKBEAT pivotal study will evaluate the efficacy and safety of atrioventricular interval modulation (“AVIM”) therapy (also known as BackBeat CNT), for the treatment of pacemaker-indicated patients with uncontrolled hypertension despite the use of antihypertensive medications. Orchestra BioMed and Medtronic, Inc. Kowal, M.D., and Europe.
105 
DAIC
MAY 6, 2024
The primary outcome measure for the study is change in six-minute walk distance from Baseline to Week 12. Results of Tenax Therapeutics’ Phase 2 HELP study of levosimendan in patients with pulmonary hypertension (PH) with heart failure with preserved ejection fraction (HFpEF) demonstrated that I.V.
Frontiers in Cardiovascular Medicine
DECEMBER 3, 2024
The purpose of this study was to examine the clinical outcomes with TCM for CVD after the recent publication of large trials adding >20,000 individuals to the published data. In most studies, TCM has been associated with significant improvements in alternative endpoints such as hypertension, coronary heart disease, stroke and heart failure.
Hypertension Journal
DECEMBER 5, 2024
Hypertension, Ahead of Print. BACKGROUND:Orthostatic hypertension is an emerging risk factor for adverse events. During up to 30 years of follow-up, orthostatic increases were not significantly associated with any of the adverse outcomes of interest, while standing SBP 140 mm Hg was significantly associated with all end points.
Frontiers in Cardiovascular Medicine
JANUARY 2, 2024
If pulmonary hypertension is additionally involved with vasoplegic syndrome, circulation management becomes much more complicated. The aim of this study is to investigate whether pituitrin is beneficial for the postoperative outcomes in patients with pulmonary hypertension undergoing cardiac surgery.
59 
DAIC
JANUARY 8, 2025
a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases, hasannounced that the U.S. We believe suppression of aldosterone production by lorundrostat has the potential to reduce the nocturnal hypertension driving adverse cardiovascular outcomes.
NEJM Journal Watch - Cardiology
NOVEMBER 13, 2024
Observational data confirm an association between longer time in target range and reduced incidence of CVD and premature death.
American College of Cardiology
JUNE 12, 2024
Eagle looks at excess apolipoprotein-B and cardiovascular risk, then examines a recent meta-analysis on treating pulmonary arterial hypertension. Finally, Dr. Eagle shares some thoughts on a SMART-C collaborative meta-analysis of sodium-glucose cotransporter-2 inhibitors and major adverse cardiovascular outcomes.
47 
Journal of the American Heart Association
FEBRUARY 3, 2025
BackgroundDespite the poor outcomes related to the presence of pulmonary hypertension, it often goes undiagnosed in part because of low suspicion and screening tools not being easily accessible such as echocardiography. Journal of the American Heart Association, Ahead of Print.
68 
American College of Cardiology
DECEMBER 20, 2024
Is chlorthalidone superior to hydrochlorothiazide in preventing kidney outcomes when used for hypertension treatment?
57 
Frontiers in Cardiovascular Medicine
DECEMBER 13, 2023
Background Hypertension has now developed into a major public health problem worldwide. Objective This study aimed to systematically evaluate the effect of acupuncture alone or in combination with antihypertensive drugs on the efficiency of reducing blood pressure and controlling blood pressure in elderly patients with hypertension.
64 
Open Heart
MARCH 3, 2025
We aimed to compare outcomes between a broad range of second-generation DP-DES and BP-DES in an all-comer population. Despite the DP-DES group exhibiting significantly higher rates of risk factors, such as arterial hypertension (63.1% Conclusion Clinical follow-up up to 2 years shows similar outcomes between BP-DES and DP-DES.
52 
Open Heart
APRIL 2, 2024
To maximie decision-making, facilitate effective patient counselling, and ultimately improve maternal and fetal outcomes as a whole, it is critical to comprehend the outcomes of SSP in women who have previously experienced PPCM. This study aimed to evaluate the outcomes of SSP in women with PPCM. to –4.09; p=0.004).
Heart BMJ
MARCH 26, 2025
2 Therefore, early identification of HF in high-risk populations, particularly post-MI, is essential for improving outcomes. Common predictors include older age, prior hypertension, diabetes and atrial fibrillation. Risk factors for developing HF after MI vary and are influenced by whether the patient has HFrEF or HFpEF.
Frontiers in Cardiovascular Medicine
FEBRUARY 5, 2024
Objective The prevalence of hyperuricemia and hypertension is steadily increasing, and these conditions often share common risk factors. This study aimed to investigate the association among hyperuricemia, hypertension, and all-cause mortality in a nationally representative U.S. population.
64 
Becker's Hospital Review - Cardiology
FEBRUARY 12, 2024
The Association of Black Cardiologists is recruiting clinicians for a new certification program it launched in December related to hypertension management. The aim is to increase culturally conscious care for patient populations that are more likely to be diagnosed with the condition and experience adverse outcomes from it.
Heart BMJ
MARCH 13, 2025
The tricuspid valve (TV), historically deemed the ’forgotten valve’, is undergoing a renaissance as mounting evidence highlights its critical role in cardiovascular outcomes. TR: the clinical burden and the need for recalibration TR has been underestimated in its impact on morbidity and mortality. 2 3 Furthermore, persistent.
52 
Open Heart
AUGUST 30, 2024
Objective To describe the impact of the pandemic on blood pressure screening and hypertension management based on a national quality of care scheme (Quality and Outcomes Framework, QOF) across key demographic, regional and clinical subgroups. Recorded hypertension prevalence was relatively stable at 15% throughout the study period.
52 
DAIC
MARCH 10, 2025
Yasser Sammour, MD, MScpresented "Long-Term Hemodynamic Performance and Clinical Outcomes in Small and Large Aortic Annuli Patients with Severe Aortic Stenosis."This The association of BVD with clinical outcomes (unadjusted for covariates) was evaluated by small and large annuli (CT annular diameter 23 vs >23 mm).
Cardiometabolic Health Congress
SEPTEMBER 20, 2024
Hypertension is a condition that requires continuous monitoring, making it an ideal candidate for telehealth and digital health innovations. Why Telehealth is Essential for Hypertension For patients with hypertension, managing blood pressure outside of the office is crucial. Who Should Use Video Visits?
Stroke Journal
DECEMBER 8, 2023
BACKGROUND:Therapeutic-induced hypertension treatment (iHTN) is helpful for alleviating early neurological deterioration (END) in acute small vessel occlusive stroke. Stroke, Ahead of Print.
75 
Heart BMJ
MAY 10, 2024
Objectives The association of pulmonary hypertension (PH) with the outcome after mitral transcatheter edge-to-edge repair (M-TEER) focusing on the new ESC/ERS guidelines definition for PH. Background PH is frequently found in patients with mitral regurgitation and is associated with lower survival rates.
Frontiers in Cardiovascular Medicine
JANUARY 22, 2024
This observation has not been investigated in hypertensives of African ancestry. We hypothesised that an individual patient data meta-analysis (IPD-MA) on the efficacy of second- or third-generation beta-blockers (STGBBs) in hypertensives of African descent may provide new insights. 3.00; P < 0.001) in hypertensive Africans.
American College of Cardiology
DECEMBER 14, 2023
What is the impact on prognosis of the 2022 ESC/ERS pulmonary hypertension (PH) guidelines on the new redefined hemodynamic threshold for the diagnosis of precapillary PH?
43 
Cardiovascular Diabetology
FEBRUARY 18, 2025
Chronic thromboembolic pulmonary hypertension (CTEPH) is a severely progressive disease that leads to right heart failure and death. Previous studies have shown that diabetes and insulin resistance (IR) are cl.
52 
CardiacWire
JANUARY 29, 2025
Bioprosthetic patients also had higher rates of hypertension (78.7% The studys design also wasnt powered to make any certain conclusions due to its reliance on registry data, meaning a randomized head-to-head trial would be needed to confirm these outcomes. vs 71.8%) or prior PCI (6.7
80
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content